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dose CsA. We agree that these renal lesions of interstitial tion, and a decrease in oxygen demand in the medulla [3].
In addition, adenosine also appears to decrease sodiumfibrosis and tubular atrophy are not necessarily followed
by a progressive loss of renal function after a treatment chloride transport in the thick ascending limb of Henle’s
of one year with CsA. However, the results of long-term loop [3] as well as to increase blood flow to the medulla
studies [refs. 69, 70, 85], that is, an increase of interstitial by dilating the vasa recta (abstract; Clin Res 36:627A,
fibrosis as a function of time, clearly indicate the progres- 1988). Adenosine administration results in a significant
sive nature of CsA-induced nephrotoxicity. increase in medullary PO2 (in conjunction with a de-
Ponticelli and colleagues state that CsA nephropathy crease in cortical PO2) [5].
is reversible after drug withdrawal. As we discussed, the Thus, I would offer an alternative interpretation to
functional impairment was reversible after withdrawal the observations by Erley et al. While adenosine unques-
of CsA, complete in six studies, but only partial in seven tionably decreases renal function (renal blood flow, glo-
studies. However, follow-up studies after withdrawal merular filtration rate, and reabsorption), this may con-
clearly show that a subgroup of patients still has in- stitute a protective effect, preserving renal viability and
creased levels of serum creatinine 20 to 24 months after assuring better renal function after ischemic insult to the
cessation of the drug [refs. 57 and 64]. Moreover, the kidneys. Oliguria is a sign of a decreased renal function
morphological changes induced by CsA are not revers- which may be interpreted as “acute renal success” [6].
ible and progress in a function of time. Perhaps we should postpone using adenosine antagonists
We agree that short-term treatment of CsA according in the clinical setting in question until further studies on
to the dosage guidelines has an acceptable risk of pro- high-risk patients reveal the truth.
gressive renal dysfunction, but we strongly fear that long-
Simon Gelman and Nicholas Sadovnikoffterm therapy of more than one year will lead to a progres-
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with doses of CsA below 5 mg/kg/day. The necessity of
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ease should therefore be carefully evaluated against the
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1976To the Editor: The interesting and impeccably de-
signed study by Erley et al convincingly demonstrates
the role of adenosine and adenosine receptors in renal Reply from the authors
function [1]. However, their tentative conclusion, that
To the Editor: We express concern about the interpre-adenosine antagonists would be effective in preventing
tation and “tentative conclusion” of our paper, in whichrenal impairment following radiocontrast-medium ad-
we recommend the use of adenosine receptor antagonistsministration is not justified by the study and may be
in the prevention of renal functional impairment followingwrong. There is a fundamental difference between renal
administration of radiocontrast media, especially in thefunction and renal viability. Adenosine constricts pre-
presence of additional risk factors [1]. Instead, Gelmanglomerular vessels and dilates post-glomerular vessels
and Sadovnikoff present an alternative interpretation of(via A1 and A2 receptors, respectively) [2–5]. This re-
our findings, based upon an assumption of a “fundamentalsults in a significant decrease in intra-glomerular pres-
difference between renal function and renal viability.”sure and a decrease in glomerular filtration rate. This is
The authors argue that a decline in renal function wouldexactly what the authors observed. However, a decrease
represent an “acute renal success,” as termed by Thurauin glomerular filtration would result in a decrease in solute
and Boylan [2]. In this context, however, we feel thatdelivery to the tubulae, a decrease in the tubular reabsorp-
this represents an incomplete interpretation of the renal
response to tubular injury, since Thurau and Boylan
described “acute renal success” as a conservation of sys- 1999 by the International Society of Nephrology
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temic fluid homeostasis on the cost of acute glomerular results obtained in L-NAME pretreated rats in contrast
to normal rats [1, 4].shutdown, that is, the kidney sacrifices its function to
In clinical settings one efficacious method in preventingassure survival of the organism.
renal functional impairment is hydration of the patientWe agree with Gelman and Sadovnikoff that in the
prior to application of nephrotic substances. However,kidney the principle of organ protection might be real-
under conditions such as congestive heart failure, whenized by the way of transient renal functional impairment
hydration cannot be carried out, administration of aden-
to reduce the work load of the kidney. Adenosine was osine receptor antagonists may present a true therapeutic
proposed as a mediator of the metabolic control of kid- alternative [5].
ney function [see Refs. in 3]. The point, however, is that
Christiane M. Erley, Nils Heyne and Hartmut Ossaldseverity, duration, and reversibility of renal functional University of Tu¨bingen, Tu¨bingen, Germany
impairment cannot be predicted in the initial phase of
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